← All trials
NCT00555997
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2008
- Primary completion
- Jun 1, 2010
- Completion date
- Jun 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Psychiatric Medicine Associates, L.L.C.Overall official - principal investigator
- Comprehensive Psychiatric Care, Norwich CTOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of ConnecticutCollaborator
- Vanderbilt UniversityCollaborator
- Cedars-Sinai Medical CenterCollaborator
- Harvard UniversityCollaborator
- Psychiatric Medicine Associates, L.L.C.Collaborator
- Harvard UniversityReponsible party - principal investigator
- Cedars-Sinai Medical CenterOverall official - principal investigator
- University of ConnecticutOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.